Patrick Trojer, Ph.D.
Dr. Patrick Trojer joined Constellation Pharmaceuticals as a founding scientist in 2008 and currently serves as Chief Scientific Officer. Patrick has held multiple positions of increasing responsibility at Constellation. Among his many achievements, he drove Constellation’s EZH2 program, leading to the clinical launch of CPI-1205. Patrick is internationally recognized for his expertise in chromatin biology and its control of gene transcription, has authored dozens of scientific publications and is a frequent lecturer in the epigenetics space. Patrick completed his postdoctoral studies at NYU Medical School in Dr. Danny Reinberg’s laboratory, prior to which he received both a Ph.D. in protein biochemistry and molecular biology and M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.